Synthesis an‎d characterization of gold nanoparticles conjugated to doxorubicin an‎d antibody for targeted drug delivery to cancer cells

10/22/2026 12:00:00 AM

Recently, gold nanoparticles have found application in the medical field, due to their unique an‎d diverse properties such as small size, biocompatibility, high chemical an‎d physical stability, high drug loading capacity, low toxicity, an‎d functional versatility. In addition, they offer the possibility of developing innovative therapies. Our aim is to develop a novel bioconjugate (DOX-AuNPs-Bev), consisting of gold nanoparticles (AuNPs) conjugated to the chemotherapeutic agent doxorubicin (DOX) an‎d a monoclonal antibody for the combined treatment of breast cancer by chemotherapy an‎d immunotherapy, which can deliver the drug to cancer cells in a targeted manner while reducing systemic toxicity. In this regard, doxorubicin was attached to the nanocarrier via a hydrazone group to enable its pH-sensitive an‎d specific release in the acidic environment of the tumor. Doxorubicin exerts its cytotoxic effect by inhibiting DNA synthesis an‎d preventing cancer cell proliferation. Simultaneously, using cysteamine, the bevacizumab antibody was attached to the surface of the nanoparticles so that the system could specifically target cancer cells with high expression of vascular endothelial growth factor. Antibody binding causes the nanocarriers to actively bind to target cells in the body environment, preventing off-target uptake by the immune system an‎d increasing drug accumulation in tumor tissue. Drug release from the nanocarrier was also investigated through laboratory methods. Finally, various physicochemical methods were used to prove an‎d examine the carrier, an‎d the interpretations revealed that the carrier structure was prepared as expected.

سرطان , اثر سيتوتوكسيك , آنتي بادي مونوكلونال

cancer , cytotoxic effect , Monoclonal antibody

Abedi

Dr.Maleki